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Flow obstruction of continuous-flow ventricular assist devices. 
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To the Editor, 
 
Left ventricular assist devices (LVAD) are a success story in the treatment of patients with advanced 
heart failure, but their use is limited by the incidence of adverse events. One of the more serious 
complications is device thrombosis. With third generation devices, the incidence rate for thrombosis is 
between 1.35 and 0.5/100 patients/mo, and thrombosis is more common within the pump. The incidence 
of intrapump thrombosis has been reduced by technological advances1; however, LVAD flow can also be 
obstructed, albeit less frequently, by torsion, thrombosis, or stenosis affecting the outflow graft (4% of 
thrombosis events).2 
 
We present the case of a 72-year-old male patient with advanced heart failure in INTERMACS profile 3 
who received a HeartWare HVAD System (Medtronic, United States) as destination therapy. The LVAD 
was implanted via left lateral thoracotomy and upper ministernotomy. The outflow graft was anastomosed 
in the ascending aorta. The patient was anticoagulated with sodium heparin in the first 24 hours after 
implantation and was subsequently placed on oral anticoagulation 
therapy with acenocoumarol and antiplatelet therapy with 150 mg/d aspirin. The HeartWare HVAD 
parameters at discharge were as follows: speed, 2700 rpm; power, 3.6 W; and estimated flow, 3.9 
L/min. Echocardiography confirmed intermittent opening of the aortic valve. 
 
The patient's immediate clinical course was favorable. However, after the fourth month, he began to have 
events related to hemocompatibility. There were 2 episodes of severe anemia secondary to 
occult gastrointestinal bleeding that required temporary suspension of antiplatelet and anticoagulation 
therapies, management to achieve an INR of 2-2.5, and initiation of chronic treatment with slow-
release octreotide. The patient also had a transient ischemic attack in the right middle cerebral artery. 
 
LVAD follow-up revealed a progressive decline in estimated flow but with stable power despite blood 
volume optimization. This was accompanied by a decline in flow pulsatility and hemolysis data showing 
progressive increases in lactate dehydrogenase levels and haptoglobin metabolism, despite good INR 
control except during the bleeding episodes. Echocardiography revealed evidence of insufficient left 
ventricular emptying: aortic valve opening in all heartbeats, moderate mitral regurgitation, and 
displacement of the interventricular septum to the right. Thoracic computed tomography revealed stenosis 
of the anastomosis between the outflow graft and the ascending aorta (figure 1A,B). The outflow graft 
was at a 90° angle to the aorta and there was no evidence of thrombotic material, thus 
indicating torsion of the graft. Given the evidence indicating hemodynamically significant stenosis, the 




Figure 1. A and B, Thoracic computed tomography showing the stenosis (solid arrows) located at the level of 
the anastomosis of the outflow graft (triangle) with the ascending aorta (asterisk). C, Postprocedure computed 
tomography 3-dimensional reconstruction showing the implanted stent (dashed arrow). 
The procedure was carried out in the catheterization laboratory using a retrograde approach via the 
outflow graft. The patient was previously fitted with a SENTINAL cerebral protection device (Boston 
Scientific, United States). A 10/30 mm Formula stent (Cook Medical, United States) was placed in the 
outflow graft stenosis, followed by dilation with a 12 mm balloon (figure 1C). 
 
Hemodynamic data and LVAD parameters during the procedure are shown in table 1. 
Postprocedure echocardiography showed complete closure of the aortic valve, disappearance of the mitral 
regurgitation, and midline positioning of the interventricular septum, indicating appropriate 
decompression of the left ventricle by the LVAD. After the procedure, the patient was placed on 
dual antiplatelet therapy with 100 mg/d aspirin and 75 mg/d clopidogrel and was anticoagulated to a 
target INR of 2–3. Lactate dehydrogenase levels normalized, and the patient has had no 
further gastrointestinal bleeding events during 6 months of follow-up. 
Table 1. LVAD parameters and hemodynamic variables before and after dilation of the outflow graft 




SBP, mmHg  DBP, mmHg  MBP, mmHg  SBP, mmHg  DBP, mmHg  MBP, mmHg 
Pre-PI Post-PI  Pre-PI Post-PI  Pre-PI Post-PI  Pre-PI Post-PI  Pre-PI Post-PI  Pre-PI Post-PI Pre-PI Post-PI 
                   
200 124  130 105  155 110  83 85  41 78  60 81 95 29 
                   
 
LVAD data 
Speed, rpm  Power, W  Flow, L/min  Pulsatility, L/min 
Baseline Pre-PI Post-PI  Baseline Pre-PI Post-PI  Baseline Pre-PI Post-PI  Baseline Pre-PI Post-PI 
               
2700 3200 3200  3.6 6.2 6.3  3.9 2.3 4.4  2.5 1 3.5 
               
 
DBP, diastolic blood pressure; LVAD, left ventricular assist device; MBP, mean blood pressure; PI, percutaneous intervention; rpm, revolutions per minute; SBP, systolic blood pressure. 
 
This patient's case illustrates an uncommon problem that highlights 2 issues. The first is the importance of 
investigating and treating chronic hemolysis in patients with an LVAD, a situation that reduces survival 
and increases the rate of adverse events.3 The second issue is the influence of the surgical method on the 
prevention of adverse events. In the case presented here, the sharp angle of the anastomosis could have 
caused the hydrodynamic forces and turbulence to progressively increase the flow obstruction and 
produce progressive torsion of the outflow graft.4 While the choice of approach will depend on the size 
and location of the stenosis, percutaneous treatment is useful and safe in selected patients. 
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